No updates on the Optomed Aurora AEYE FDA clearance process
Optomed Plc Stock Exchange Release 29 April 2024 at 13:20, Helsinki
No updates on the Optomed Aurora AEYE FDA clearance process
Optomed is together with its partner AEYE Health in the process of obtaining a clearance for the AI fundus camera Optomed Aurora AEYE.
At this stage, Optomed does not have any new information regarding the FDA clearance process. Optomed will update market as new information becomes available.
Optomed Plc
Further enquiries
Juho Himberg, CEO, juho.himberg@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally